Molecular signatures of non-typeable *Haemophilus influenzae* lung adaptation in

paediatric chronic lung disease

Ammar Aziz[1], Derek S. Sarovich[1,2], Elizabeth Nosworthy[1], Jemima Beissbarth[1], Anne B.

Chang[1,3], Heidi Smith-Vaughan[1], Erin P. Price[1,2,*,^] and Tegan M. Harris[1,^]

[1]Child Health Division, Menzies School of Health Research, Charles Darwin University, Tiwi,

NT, 0810, Australia

[2]GeneCology Research Centre, University of the Sunshine Coast, Sippy Downs, QLD, 4556,

Australia

[3]Department of Respiratory and Sleep Medicine, Children's Health Queensland, Queensland

University of Technology, Brisbane, QLD, Australia

[^]Authors contributed equally

*Correspondence:

Dr. Erin P. Price

eprice@usc.edu.au

Keywords: Non-typeable *Haemophilus influenzae*, NTHi, RNA-seq, transcriptomics,

comparative genomics, convergence, bacterial evolution

Running Title: Signatures of NTHi paediatric lung adaptation

Abstract

Non-typeable *Haemophilus influenzae* (NTHi), an opportunistic pathogen of the upper

airways of healthy children, can infect the lower airways, driving chronic lung disease.

However, the molecular basis underpinning NTHi transition from a commensal to a pathogen

is not clearly understood. Here, we performed comparative genomic and transcriptomic

analyses of 12 paired, isogenic NTHi strains, isolated from the nasopharynx (NP) and

bronchoalveolar lavage (BAL) of 11 children with chronic lung disease, to identify convergent

molecular signatures associated with lung adaptation. Comparative genomic analyses of the

12 NP-BAL pairs demonstrated that five were genetically identical, with the remaining seven

differing by only 1 to 3 mutations. Within-patient transcriptomic analyses identified between

2 and 58 differentially expressed genes in 8 of the 12 NP-BAL pairs, including pairs with no

observable genomic changes. Whilst no convergence was observed at the gene level;

functional enrichment analysis revealed significant under-representation of differentially

expressed genes belonging to *Coenzyme metabolism, Function unknown, Translation,*

ribosomal structure and biogenesis Cluster of Orthologous Groups categories. In contrast,

Carbohydrate transport and metabolism, *Cell motility and secretion*, *Intracellular trafficking*

and secretion, and *Energy production* categories were over-represented. This observed trend

amongst genetically-unrelated NTHi strains provides evidence of convergent transcriptional

adaptation of NTHi to paediatric airways that deserves further exploration. Understanding

the pathoadaptive mechanisms that NTHi employs to infect and persist in the lower

paediatric airways is essential for devising targeted diagnostics and treatments aimed at

minimising disease severity, and ultimately, preventing NTHi lung infections and subsequent

chronic lung disease in children.

Importance

Non-typeable *Haemophilus influenzae* (NTHi) is a pathogen with increasing public health

recognition. Once established in the lower airways, NTHi can facilitate the infection of other

pathogenic bacteria, with its presence associated with increased risk of developing

bronchiectasis. To elucidate the mechanisms by which NTHi infects the lower airways, we

compared the genomes and transcriptomes of 12 paired isolates from 11 children with

chronic lung disease. Genomic comparisons identified alterations in several phase-variable

and antigenic genes. Unlike NTHi isolated from diseased adult airways, no mutations were

observed in *ompP1* in our cohort, suggesting strong stabilising selection in paediatric airways.

Transcriptomic analyses identified a parallel signal of pathoadaptation, with over-

representation of genes in key functional categories, most of which were down-regulated.

These results suggest a complex but ultimately predictable strategy employed by NTHi to

colonise paediatric lower airways. Understanding these transcriptional pathoadaptive

strategies will enable better treatment and prevention of NTHi lung infections in children.

Introduction

Non-typeable *Haemophilus influenzae* (NTHi) is a Gram-negative bacterium that frequently colonises the respiratory tract mucosa of humans. NTHi is part of the upper airway flora and is found in 20-50% of healthy children and 20-30% of healthy adults (1). The upper airways may act as a reservoir for seeding the lung environment (2), where NTHi switches to an opportunistic pathogenic lifestyle, a transition driven by multiple, poorly understood factors (3).

NTHi facilitates the colonisation of other bacterial species in the lower airways (4) and is associated with exacerbations in several respiratory diseases (3). Indeed, its presence in the lower airways is associated with increased risk of future development of bronchiectasis (5). In children with chronic suppurative lung disease (CSLD) or bronchiectasis, NTHi is the most commonly detected bacterium in the lower airways (6). In adults, the bacterium can chronically and repeatedly colonise the lungs of patients with chronic obstructive pulmonary disease (COPD), bronchiectasis, or COPD with bronchiectasis (7, 8), resulting in increased airway inflammation (9). NTHi also has the capacity to form biofilms (10, 11) resulting in a decreased susceptibility to antibiotics and increased inflammatory and defence responses in the host (12). Unsurprisingly, NTHi is a pathogen with increasing public health recognition (4, 13).

NTHi has evolved several adaptive mechanisms that enable the bacterium to survive and persist in the human host, including modification of its genome via homologous recombination and phase variation (14, 15). Modulation of gene expression through phase variation enables NTHi to rapidly adapt to and colonise new environments (16). Analysis of the NTHi genome has identified several phase-variable virulence factors involved in

persistence, nutrient uptake, cellular adherence, and host immune response evasion (17),

with direct modulation of gene expression in response to environmental stimuli and host

milieu (18). NTHi is naturally competent and can undergo high rates of recombination,

resulting in greater genetic and phenotypic diversity than serotypeable *H. influenzae* (19);

however, unlike other chronic respiratory infections (20, 21), no significant gene loss or gain

has yet been observed in chronic *H. influenzae* infections (17).

Identifying signals of NTHi adaptation to the lung would aid in unmasking the mechanisms

facilitating pathogenesis, which is critical for improving diagnosis, treatment and prevention

of NTHi-associated lower airway diseases. The mechanisms involved in the transition from a

commensal state in the nasopharynx (NP) to a pathogenic lifestyle in the lower airways is not

well understood (17, 22). In this study, we investigated genome- and transcriptome-wide

differences between 12 isogenic NTHi pairs obtained from the NP and lower airways (via

bronchoalveolar lavage; BAL) of patients with bronchiectasis or CSLD. We hypothesised that

NTHi isolated from the airways of patients with lung disease would exhibit characteristic

genetic or transcriptional profiles that signalled a change from a commensal to a pathogen.

Methods

Isolate Collection. NP swabs and BAL specimens were collected concurrently from Australian

children (mean, 3.2 years; range: 1.1-13.9 years) diagnosed with bronchiectasis or CSLD (Table

1) at participating hospitals in the Northern Territory and Queensland (23). Following

collection, specimens were transported on ice in 1 mL skim milk, tryptone, glucose and

glycerol broth (STGGB) (23, 24) and stored at -80°C before processing. All subsequent cultures

were also stored in STGGB at -80°C. Following selective culture on chocolate blood agar (CBA)

supplemented with bacitracin, vancomycin, and clindamycin (Oxoid, Scoresby, VIC, Australia),

NTHi was isolated and confirmed as previously described (23, 25). Antibiotic sensitivity was

determined by disc diffusion as per the Calibrated Dichotomous Susceptibility (CDS) testing

guidelines (8th Edition) (26) for ampicillin, amoxicillin-clavulanate, cefaclor, ceftriaxone,

chloramphenicol, tetracycline and azithromycin.

Whole-Genome Sequencing and Comparative Genomics. DNA extraction was performed as

previously described (27). Whole-genome sequencing (WGS) was carried out at the Australian

Genome Research Facility (Parkville, VIC, Australia) using the Illumina (San Diego, CA, USA)

HiSeq 2500 platform. As a criterion for our study, all isolate pairs were required to be highly

genetically similar (i.e. isogenic). To identify isogenic NP-BAL pairs from each patient,

multilocus sequence typing (MLST) (28) followed by phylogenetic analysis was performed.

Further details on isolate selection is described in Text S1. Based on this analysis, we selected

12 paired NP-BAL isolates from 11 patients for further investigation; two genetically distinct

NP-BAL pairs were selected from one patient (designated 60373_P1 and 60373_P2).

To catalogue the mutations separating each NP-BAL pair, SPANDx v3.2 (default settings) (29)

was used. Where possible, genetic variants were also confirmed using transcriptomic (RNA-

seq) data. For each analysis, the NP isolate draft assembly was used as the reference for

variant calling. Further details are provided in Text S1.

NTHi Liquid Media Growth Conditions for RNA Harvest. Due to the reliance of NTHi growth

on the presence of X (haemin/haematin) and V (nicotinamide-adenine-dinucleotide) blood

factors (30), we initially attempted to culture isolates in brain heart infusion (BHI) broth

supplemented with Haemophilus Test Medium (HTM; Oxoid), and subsequently, a HTM-

supplemented artificial sputum medium formulated to mimic the mucosal environment in the

airways of cystic fibrosis patients (25, 31). However, due to inconsistent optical density (OD)

readings and poor growth or flocculation of some or all isolates in these media, we

investigated an alternative liquid medium for the growth of NTHi for RNA-seq (see Text S1 for

further details). CBA is widely used for culturing NTHi and other fastidious bacteria (32). Thus,

we used this medium as the basis for formulating liquid chocolate medium (LCM).

Formulation of LCM and growth conditions are provided in Text S1.

RNA Extraction. All isolates were cultured in LCM and in duplicate to account for any technical

replicability issues. RNA was extracted using TRIzol® as described in Text S1. After DNA digest,

absence was verified using real-time PCR assays that detect Hi DNA (33) and defibrinated

horse blood DNA (34). For further details see Text S1.

Differential Expression (DE) Analysis. RNA-seq processing and DE analysis was performed as

described in Text S1. Breifly, RNA-seq was carried out using the Illumina HiSeq 2500 platform.

In total, 24 isolates were sequenced in duplicate, generating 48 transcriptomes.

To identify molecular signatures of lung adaptation on a within-patient basis, DE analysis was

first conducted by comparing BAL with NP isolates from individual patients. Subsequently,

convergence analysis was performed by comparing BAL with NP isolates from all 12 isolate

pairs. The following additional analyses with different sample sets were performed to ensure

robustness: a) those NP-BAL pairs with DE detected in the within-patient analysis (eight in

total), and b) the three NP-BAL pairs with >45 DE genes (60051, 60068, 60295). For all

convergence analyses, the two NP-BAL pairs from patient 60373 were treated either as

independent NP-BAL pairs or grouped as a single patient. DE was conducted using edgeR

(v3.18.1) (35), implemented in R (v3.4.1) (36). For all analyses, DE was determined using the

quasi-likelihood method (*glmQLFit* function).

Genes with significant DE were annotated using Clusters of Orthologous Groups (COG) (37),

with categories retrieved from a previous study (38) with minor corrections (Table S1). For

genes with multiple COG categories, all assigned categories were included in the analysis. To

assess for significant enrichment of functional groups, COG categories of the reference

genome 86-028NP were compared with those identified in the within-patient DE analyses.

Statistical assessment comparing the proportion of categories was performed in R using a

two-tailed Fisher's exact test with a false discovery rate corrected *p*-value of ≤0.05.

Data Availability. All genomic and transcriptomic data generated as part of this study are

publicly available under NCBI BioProject PRJNA484075. Genome assemblies for the 24 NTHi

strains can be found in NCBI GenBank (SAMN9845260-SAMN9845283), and Illumina WGS and

RNA-Seq data are available on the Sequence Read Database (SRR7719256-SRR7719303).

Results

Comparative Genomic Analysis of Paired Isolates. To assess diversity and to identify

potential clustering of NP or BAL isolates, a maximum parsimony phylogenetic tree was

constructed using 124,262 biallelic, core-genome SNPs identified among the paired isolates

and a global NTHi isolate set comprising 157 strains (Figure S1). Phylogenomic analysis

confirmed that pairs from individual patients clustered closely together yet were distinct from

other NP-BAL pairs. Consistent with previous studies (17, 22, 27), there was no evidence of

NP- or BAL-specific clades. Isolate pairs were identical sequence types (STs), with 5 of the 12

pairs possessing novel STs (ST-1906 to ST-1910; Table S2). Patient 60373 had two distinct

isolate pairs (NP-BAL pairs 60373_P1 and 60373_P2) that were separated by >17,000 SNPs,

demonstrating the presence of at least two NTHi lineages colonising this patient. This finding

was also reflected in the MLST data, with 60373_P1 isolates belonging to ST-1910 whereas

60373_P2 isolates were ST-139 (Table S2). Antibiotics are routinely used to treat exacerbation

events in paediatric chronic lung disease, and resistance to clinically-relevant antibiotics can

arise during such infections. In the current work, no NTHi isolate exhibited resistance towards

any of the tested antibiotics, ruling out antibiotic resistance-driven mutations arising between

isolate pairs.

Next, within-patient comparative genomic analyses were performed to identify variants

separating the paired NP-BAL isolates. Pairs were highly genetically similar, with a maximum

of three mutations observed between any one pair (Table 1). In total, two non-synonymous

SNPs and seven indels (six in open-reading frames) were identified among seven NP-BAL pairs,

with the remaining five NP-BAL pairs being genetically identical (Table 2). No copy-number

variants, large deletions or inversions were observed between any of the pairs. One non-

synonymous SNP occurred in the exogenous haem acquisition-encoding gene, *hgpB*

(HgpB$_{Arg407Lys}$; 60295 BAL Hi1), and the second affected the outer membrane protein assembly

factor, *bamA* (BamA$_{Glu508Gly}$; 65290 NP Hi3). Of the seven indels, four were simple sequence

repeats (SSRs) that were predicted to result in frameshift mutations, leading to truncated

proteins in phase-variable genes (HsdM3$_{Glu9fs}$, HsdM3$_{Glu12fs}$, HgpB$_{Thr35fs}$, and Lic3A$_{Ser18fs}$ in

60051 BAL Hi1, 60373_P1 BAL Hi1, 60068 BAL Hi1, and 65001 BAL Hi1, respectively). The

remaining three indels were in: *ompP2* (OmpP2$_{Ala269\_Gly270insValGlyAla}$; 65001 BAL Hi1), *hsdS2*

(HsdS2$_{Thr173\_Leu176del}$; 65001 BAL Hi1), and an intergenic region 62bp upstream of *hxuC* (60069

BAL Hi1). Notably, *hsdM3* (in 60051 and 60373_P1) and *hgpB* (in 60068 and 60295) were

mutated in isolates from two patients. When compared with 86-028NP, all mutations were

shown to deleteriously affect the BAL isolates (Table 2).

The *hsdM3* indels in both the 60051 and 60373_P1 BAL isolates occurred in the same

pentanucleotide SSR tract, which comprises variable copy number of a 'CGAGA' motif at the

5' end of this gene. Phase variation in *hsdM3* is driven by changes in this highly mutable SSR

tract and is influenced by a lack of adenine methylation (39). A 5bp AGACG deletion in this

SSR tract in 60051 BAL Hi1 (Figure 1A and 1C) is predicted to produce a truncated protein of

just 13 residues. Similarly, a 5bp CGAGA deletion was observed in 60373_P1 BAL Hi1;

however, it was only supported by ~60% of aligned reads. Upon closer inspection, a 10bp

deletion (CGAGACGAGA) was present in the remaining ~40% of aligned reads (Figure 1B). This

mixture of *hsdM3* alleles is supported by the RNA-seq reads. The 5bp (~60%) and 10bp (~40%)

components were both predicted to produce a truncated protein of 16 and 24 residues,

respectively (Figure 1C). Given that isolates were subjected to a genetic bottleneck prior to

sequencing, these mixtures suggest that the *hsdM3* SSR undergoes a rapid mutation rate,

with mutations potentially occurring during laboratory passage.

Liquid Chocolate Medium for Reproducible NTHi Growth. As NTHi has an absolute growth requirement for X and V blood factors (30), commonly used culture media for this fastidious bacterium typically includes lysed blood in a nutrient-rich agar base (e.g. CBA) (32), or BHI base supplemented with HTM (40). However, we found uniform and reproducible growth of NTHi in HTM-supplemented BHI problematic; variable growth rates were observed both among isolates and between technical replicates, indicating inconsistent bacterial growth. Additionally, the microbial load was insufficient for RNA-seq, even after 24h incubation. We also observed inconsistent OD readings between replicates and a tendency towards flocculation in certain strains. Similar issues were observed with HTM-supplemented artificial sputum medium, which is designed to mimic cystic fibrosis sputum (31) (Figure S2A).

To overcome these issues, we developed liquid chocolate medium (LCM), a medium that is straightforward to formulate, inexpensive and produces high-quantity NTHi cellular density for downstream analysis. LCM yielded NTHi cultures with reproducible growth, consistent growth rates, little to no flocculation, and sufficient microbial load to support sequencing of late-log phase RNA. LCM was thus used to determine the growth curves of four isolates to identify an appropriate culture duration for RNA extraction. A 7.5-hour post-inoculation time point was found to represent late-log phase growth in all four cultures tested (Figure S2B). This time point, which was chosen to reflect non-logarithmic bacterial growth rates *in vivo* (41, 42), was subsequently used for RNA extraction of all isolates.

Within-patient DE and Comparison with Genetic Mutations. Culture and RNA extraction of 24 isolates was performed in duplicate. On average, 89.2% (87.1-92.0%) of sequence reads aligned uniquely to the 86-028NP reference genome, and of these, an average of 70% (68.2-74.8%) were assigned to known genomic features (Table S2). Due to this high mapping

percentage, within-patient DE analysis was performed using 86-028NP as the reference

genome. This approach also greatly simplified comparisons among patients. DE was observed

between eight NP-BAL pairs, ranging from 2 to 58 DE genes per pair. Three pairs (60051,

60068, and 60295) had >45 DE genes, five pairs (60362, 60370, 60373_P1, 60373_P2, and

65290) had 15 or fewer DE genes (Dataset S1), and the remaining four pairs (60069, 60294,

60316, and 65001) did not exhibit any DE.

In total, 189 DE genes, representing a wide functional spectrum, were detected across the

eight NP-BAL pairs. Eight genes were DE in three pairs (*comE*, *comM*, *glgC*, *ligA*, *pilB*, *pilC*, *smf*

and *tnaA*), 39 were DE in two pairs (*arcC*, *argF*, *asnA*, *comABCDF*, *dmsC*, *glgABPX*, *glpK*, *hitA*,

hsdMS3, *licBC*, *mao2*, *nagAB*, *nanAEK*, *NTHI0229*, *NTHI0232*, *NTHI0235*, *NTHI0646*, *NTHI0647*,

NTHI1183, *NTHI1243*, *nrfCD*, *pckA*, *pilA*, *sdaA*, *siaT*, and *tnaB*), and the remaining 87 were DE

in single NP-BAL pairs (Figure 2; Dataset S1). However, only ten genes exhibited concordant

downregulation (*mao2*, *NTHI0646*, *NTHI0647*, *pckA*, *sdaA*) or upregulation (*asnA, hitA,*

hsdMS3, *hsdS3, tnaB*) in the BAL isolates. In all other DE genes, discordance in the

directionality of expression was observed, including the eight shared DE genes in three NP-

BAL pairs (Figure 2). Additionally, genes in the 60295 pair were predominantly upregulated,

whereas genes were predominantly downregulated in pairs 60051 and 60068. Overall, there

was little overlap amongst patients.

There was also minimal correlation between the number of genetic mutations and the

number of DE genes detected between NP-BAL pairs (Table 1). For example, the 60295 NP-

BAL pair exhibited 46 DE genes, but only a single non-synonymous SNP (HgpB$_{Arg407Lys}$) was

observed in the BAL isolate. In contrast, no DE was detected between the 65001 NP-BAL pair

(Dataset S1), despite three indels being identified in the BAL isolate, including a deleterious

frameshift in the phase-variable sialyltransferase gene, *lic3A*, which truncates the Lic3A

protein from 320 to just 36 residues (Table 2). Two NP-BAL pairs (60294 and 60316) contained

no mutations and no DE genes. Conversely, two NP-BAL pairs (60051 and 60373_P1)

contained both genetic and transcriptional alterations affecting a single phase-variable gene,

hsdM3 (Table 2; Dataset S1). For both pairs, *hsdM3* and *hsdS3* were upregulated in the BAL

isolates, with an average $\log_2$ fold change of 2.5 and 4.6, respectively. Additionally, *hsdR3* was

upregulated by 2.2-fold in 60373_P1. However, both BAL isolates from 60051 and 60373_P1

encode truncated HsdM proteins of 13 and 16-24 residues, respectively (Figure 1C), indicating

that *hsdM3* upregulation in these isolates is unlikely to have a functional consequence.

Notably, the two isolates with mutations in *hgpB*, 60068 BAL Hi1 and 60295 BAL Hi1, both had

a relatively high amount of DE, with 55 and 46 DE genes, respectively.

DE Convergence and Functional Enrichment Analysis of NP-BAL Isolates. We compared BAL

with NP isolates from all patients to identify genes with convergent gene expression.

However, no single convergent genetic mutations or DE genes were identified, suggesting

more complex pathways involved in lung adaptation. Therefore, we conducted a functional

enrichment analysis of the 134 non-redundant DE genes using COG assignments to identify

enriched categories. Statistical analysis identified 4/21 COG categories that were significantly

over-represented in the functional enrichment analysis (*Carbohydrate transport and*

metabolism, *Energy production and conversion*, *Intracellular trafficking and secretion*, and

Cell motility and secretion), and 3/21 categories (*Translation, ribosomal structure and*

biogenesis, *Coenzyme metabolism*, and *Function unknown*) that were under-represented

($p \leq 0.05$, Figure 3). Of note, the *Function unknown* category encompasses 20.2% genes in the

86-028NP genome, yet DE was only observed in 3.5% of these genes. The basis for this under-

representation may partly reflect the artificially high number of gene annotations in the NTHi

genome. In support of this notion, 47/397 (11.8%) genes assigned to the *Function unknown*

category exhibited zero reads across our 48 transcriptomes (Dataset S2, grey shaded rows),

representing 37.9% of all genes with zero reads. Approximately 51.8% of the other genes with

zero reads corresponded with paralogous ribosomal and transfer RNA species (Dataset S2).

The most significant over-represented COGs ($p < 0.001$) were *Carbohydrate transport and*

metabolism, which is represented by 4.9% of 86-028NP genes, yet 17.3% of DE genes

belonged to this category, and *Cell motility and secretion*, with only 0.6% genes in 86-028NP

but with 5.8% of DE genes belonging to this COG. The most significant under-represented

COGs were *Translation, ribosomal structure and biogenesis*, comprising 8.0% of 86-028NP

genes but only 0.6% of the DE genes, and *Function unknown*, which comprises 20.2% of 86-

028NP genes yet only 6.2% of DE genes belonged to this category (Figure 3; Dataset S1). Other

significant COG categories ($p < 0.01$) were *Energy production and conversion* (5.0% of 86-

028NP genes but 12.0% DE genes) and *Coenzyme metabolism* (4.4% 86-028NP genes but 0%

DE genes).

Discussion

NTHi is a pathogen of emerging public health importance (4, 43). Conventionally considered a commensal of the upper airways, it is now recognised that NTHi is associated with increased severity and progression of multiple polymicrobial diseases of the lower airways such as COPD, bronchiectasis, and CSLD (44, 45). In this study, we aimed to identify signals of NTHi pathoadaptation to the lower airways using 12 paired isogenic strains retrieved from the upper (NP) and the lower (BAL fluid) airways of 11 paediatric patients with CLSD or bronchiectasis. Similar studies have employed WGS to document the genome-wide changes leading to chronic adaptation and persistence of NTHi retrieved from COPD sputum in adults (17, 46). The current work expands on these prior studies by examining both the genomic and transcriptomic profiles of NTHi adaptation in children's airways. To ensure isolates were retrieved from the lower airways, we obtained NTHi isolates from the lower airways (BAL fluid) rather than sputum, the latter of which is fraught with upper respiratory tract contamination issues (47).

As part of our study criteria, only isogenic strains were selected to simplify the identification of convergent pathoadaptive mechanisms. As expected, comparative genomic analyses found minimal genetic differences between all isogenic NP-BAL pairs, with only nine total variants in our dataset, ranging from zero to three variants per pair. Five pairs were genetically identical, with the remaining seven encoding a total of two SNPs and seven indels. Notably, four of these indels occurred in tandem repeat regions, or SSR tracts, of phase-variable genes, which are abundant in the NTHi genome (17, 48). SSRs provide a rapid mechanism for gene expression modulation and adaptation (49, 50). Two SSR indels occurred in the hypervariable Type I restriction-modification (RM) system methyltransferase gene, *hsdM3*. The remaining

SSR indels occurred in the haemoglobin-haptoglobin binding protein B-encoding gene *hgpB*,

which is involved in NP colonisation and iron acquisition (51), and *lic3A*, which encodes a

lipooligosaccharide (LOS) sialyltransferase that facilitates NTHi colonisation in different

anatomical sites (52, 53).

Our genetic findings concur with the recent studies, which found that phase variation in *lic3A*,

hsdM3 and *hgpB* are common in NTHi isolates retrieved from COPD airways (17, 46). In

addition to the *hgpB* SSR variant in 60068 BAL Hi1 that truncates the protein from 992 to 12

residues, a non-synonymous SNP (HgpB$_{Arg407Lys}$) was seen in 60295 BAL Hi1. Likewise, the SSR

region of *hsdM3* was deleteriously mutated in the 60051 and 60373_P1 BAL isolates, yielding

truncated proteins of ≤24 residues (Figure 1C). The *hsdM3* gene is part of a Type I RM system

that acts as a defence system against foreign DNA invasion by, e.g. bacteriophages (54), fine-

tuning of competence through variable methylation patterns, and in the methylation of self-

DNA that may alter gene expression (49). While the *hdsM3* mutations in the paediatric BAL

isolates would render their corresponding Type I RM systems non-functional, the phase-

variable nature of *hsdM3* enables rapid reverse switching back to an active state. Others have

shown that phase-variable RM systems allow NTHi to rapidly generate genomic and

phenotypic diversity, which may enhance survival and persistence, especially in new

environments (39, 55). Taken together, the commonality of SSR tract mutants affecting *hgpB*,

hsdM3 and *lic3A* in airway-derived isolates demonstrates that phase variation of these loci is

driven by strong diversifying selection, with this variation being key in the long-term

persistence of NTHi within the hostile lung environment.

Outer membrane porin (OmpP1 and OmpP2) mutations are also common in COPD-derived

NTHi isolates. Previous studies have identified deleterious *ompP1* mutations in ~33% of COPD

isolates, and in-frame *ompP2* mutations (i.e. missense SNPs and indels) in ~20% of COPD

isolates (17, 46). Similarly, we identified an in-frame *ompP2* mutation in the 65001 BAL Hi1

isolate that occurred in the extracellular loop six motif (56) and increased OmpP2 length by

three amino acids. However, we did not observe any genomic or transcriptomic *ompP1*

variation between our 12 NP and BAL pairs. Although our sample size is modest, this result

suggests that *ompP1* variants may be much less common in paediatric NTHi lung-adapted

strains than COPD lung-adapted strains. Biochemical profiles in COPD airways (e.g. fatty acids

with bactericidal activity against NTHi wild-type strains) (46) are potentially different to those

present in paediatric bronchiectasis or CSLD airways, which may explain the greater selective

pressure for OmpP1 inactivation in COPD airways. Further work is needed to document the

prevalence of *ompP1* mutations in a larger paediatric lung isolate cohort to examine whether

diseased paediatric airways do in fact impart different OmpP1 pressures on NTHi compared

with isolates from COPD airways.

Across the 12 within-patient DE analyses, a total of 134 non-redundant genes (range: 0 to 58)

were DE between NP-BAL pairs, with no correlation between the number of mutations and

the number of DE genes. Indeed, NP-BAL pairs 60362, 60370 and 60373_P2 were devoid of

mutations, yet DE was observed in 15, 2, and 4 genes, respectively. Likewise, 65001 BAL Hi1

encoded mutations in *lic3A*, *ompP2* and a Type I RM system specificity gene, *hsdS2*, yet no DE

was detected in this strain. This lack of correlation suggests that DE between isolate pairs is

influenced by epigenetic factors (e.g. altered DNA methylation (57)), or by unidentified

genetic mutations due to inherent limitations with short-read sequencing approaches (e.g.

insertion sequence-mediated rearrangements or variants in paralogues). Future studies

employing methylation signature detection and long-read sequencing will enable a deeper

understanding of the basis for DE in these strains.

We did not identify any DE gene(s) common to all isolates, indicating no universal expression

profile associated with lung adaptation (i.e. the BAL isolates). However, some degree of gene

convergence was observed, with eight DE genes common to three isolate pairs, and 39

common to two pairs (Dataset S1). Of these, the *com* and *pil* operons, required for the

biogenesis and function of the type IV pilus, were DE in three pairs. The type IV pilus is

involved in multiple biological roles including adherence to epithelial cells, competence,

twitching motility, biofilm formation and long-term NP colonisation (58, 59). The pathway

responsible for uptake, transport and incorporation of N-Acetylneuraminic acid (Neu5Ac) into

LOS (16, 60), was DE in two pairs. Incorporation of Neu5Ac into the LOS enhances immune

evasion and increases resistance to killing by human serum (61). Most DE genes (*n*=87)

occurred in single pairs, suggesting multiple, parallel strategies towards lower airway

adaptation. In addition, the directionality of DE was inconsistent, with gene upregulation in

some pairs and downregulation in others (Figure 2). Lack of a convergent transcriptional signal

across all strains may be due to sampling difficulties, for example, the inclusion of BAL isolates

that have yet to adapt to the lower airways or re-seeding of the NP environment with lung-

adapted strains. Greater breadth and depth of strains is needed to determine whether a

convergent signal of lung adaptation can be identified in the NTHi transcriptome.

To identify parallel signatures of adaptation to the lung environment on a broader scale, we

categorised the functions of within-patient DE genes based on COG categories. Overall,

strains isolated from the lower airways showed significant enrichment of DE genes in 7/21

COG categories. Four categories were over-represented in the DE gene dataset when

compared with their prevalence in the 86-028NP genome, with *Carbohydrate transport and*

metabolism, *Cell motility and secretion*, *Intracellular trafficking and secretion,* and *Energy*

production and conversion being significant (p <0.05 or p <0.001). In comparison, the COG

categories *Translation, ribosomal structure and biogenesis*, *Function unknown* and *Coenzyme*

metabolism were significantly under-represented (*p* <0.01 or *p* <0.001) in the DE gene

dataset, suggesting that altered expression of these gene categories is negatively associated

with lung adaptation. However, analysis of the 48 transcriptomes revealed that 11.8% genes

in the *Function unknown* category had zero reads mapping to the 86-028NP genome (Dataset

S2, grey-shaded rows), suggesting that many of these so-called genes likely do not produce

messenger RNA or proteins under any growth conditions, and may represent incorrect gene

annotations. Further RNA-seq studies of NTHi cultures grown under different conditions will

help to resolve these potential annotation issues. Another noteworthy observation was that

Carbohydrate transport and metabolism and *Energy production and conversion* collectively

contained ~35% of all DE genes and were primarily downregulated. This observation is

consistent with Baddal and colleagues, who observed the downregulation of genes involved

in NTHi central metabolism in response to environmental stimuli (18). *Intracellular trafficking*

and secretion and *Cell motility and secretion* were also over-represented in the BAL isolates

and predominately downregulated (Figure 3; Dataset S1). Taken together, these results

suggest that NTHi alters certain functional pathways in response to the lower airway

environment, suggesting a degree of predictability in adapting to this new niche. Although

further work is needed to consolidate these findings, our work sets the stage for identifying

key functional pathways that may be exploited for targeted treatment and eradication of this

pathogen.

Our study chose not to assess the wider polymicrobial community of the lower airways, as

accurate transcriptional characterisation of entire bacterial communities remains

bioinformatically challenging (62). We instead chose to focus on an in-depth genomic and

transcriptional analysis of NTHi, a species known to play a crucial role in the progression and

severity of lung disease (4, 13, 43). Genetically diverse NTHi isolates from different patients

were selected to enable identification of convergent adaptation strategies to the lung

environment of paediatric patients. Due to the necessary passaging of strains to ensure purity

and to obtain sufficient RNA material for sequencing, we cannot discount that these

procedures may have influenced the NTHi expression profiles so that they no longer represent

their *in vivo* counterparts. However, as previously demonstrated with other bacterial species,

isolates appear to maintain their expression profiles even after microbiological handling and

culturing *in vitro* (63). For future studies, we recommend maximising the number of strains

isolated from individual patients together with longitudinal sampling to better understand

pathogen adaptation over time.

In conclusion, our study provides new insights into NTHi adaptation to the lower airways in

paediatric chronic lung diseases. Through genomic and transcriptomic characterisation of 12

paired NTHi isolates from the NP and the lung, we found that NTHi employs several avenues

of pathoadaptation that enables this pathogen to persist in the lower airways. Although we

did not identify evidence of convergent pathoadaptive mechanisms at the single-gene level,

our study identified parallel DE at the functional level, suggesting that NTHi adaptation to the

paediatric airways is a complex but ultimately predictable process. The next steps require

characterising larger isolate panels using genomic and transcriptomic methods to better

understand the pathoadaptive mechanisms that enable NTHi to persist and cause disease.

Such findings will be crucial for the informed development of effective therapeutic

interventions to prevent NTHi-driven chronic lung diseases.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Author Contributions

AC conducted patient recruitment and specimen collection. EN, JB conducted specimen processing, genotyping, and DNA extractions. AA, JB, HSV, EPP, TMH conducted isolate selection. AA conducted culturing, RNA extraction, and bioinformatics analysis with supervision and assistance from DSS, EPP, TMH. AA wrote the initial manuscript draft, and DSS, EPP and TMH critically reviewed and edited the manuscript. DSS, HSV, AC, and EPP conceived of the study and DSS, HSV, and EPP obtained funding. All authors reviewed and approved the final manuscript.

Funding

This work was funded by the Channel 7 Children's Research Foundation (151068) and NHMRC Project Grant (1023781). AA was supported by an RTP scholarship from the Australian Government and an NHMRC CRE scholarship (1078557). DSS was supported by an Advance Queensland fellowship (AQRF13016-17RD2), EPP was supported by a University of the Sunshine Coast fellowship and an Advance Queensland fellowship (AQIRF0362018), and TMH was supported by an NHMRC CRE (1040830). AC is supported by an NHMRC Practitioner Fellowship (APP1154302). HSV was supported by NHMRC CRE Postdoctoral Fellowship (1040830) and NHMRC-funded HOT NORTH collaboration (1131932).

Acknowledgements

We wish to thank the Menzies School of Health Research Child Health team for assistance with microbiological aspects of this study, and Roisin Ure (NHS Greater Glasgow and Clyde, Glasgow, UK) for assistance with *H. influenzae* MLST database submission.

Figures

Figure 1. Read mapping analysis of the highly mutable *hsdM3* pentanucleotide short sequence repeat (SSR) tract in 60051 and 60373_P1 NP-BAL pairs. (A) Graphical representation of 60051 BAL Hi1 Illumina reads aligned against the *hdsM3* region of the 60051 NP Hi1 reference assembly. One allele consisting of a 5bp deletion (AGACG) was observed. (B) Graphical representation of 60373_P1 BAL Hi1 Illumina reads aligned against the 60373_P1 NP Hi1 reference assembly. Two different alleles consisting of 5bp (AGACG) and 10bp (AGACGx2) deletions were observed in the BAL isolate. (C) Amino acid alignment of *hsdM3* against reference strain 86-028NP (wild-type). NP isolates from 60051 and 60373_P1 encode the full-length protein, with minor differences resulting from the variable SSR track. Indels in the same SSR track of both BAL isolates, including the two alleles observed in 60373_P1, result in a deleterious frameshift that is predicted to yield a truncated protein of 13-24aa.

Figure 2. Heat map of differentially expressed (DE) genes identified between the NP-BAL pairs from 11 paediatric chronic lung disease patients. In total 134 non-redundant DE genes were detected across eight NP-BAL pairs. DE was observed in eight NP-BAL pairs; the remaining four pairs contained no DE. Genes were predominantly upregulated in the 60295 NP-BAL pair but predominately downregulated in the 60051 and 60068 NP-BAL pairs. The direction of $\log_2$ fold change of DE genes in BAL is colour-coded as follows: upregulation (blue), downregulation (green), no DE (tan).

Figure 3. Clusters of Orthologous Group (COG) analysis comparing the frequency of categories in the 86-028NP genome with all DE genes in the 12 NP-BAL pairs. Seven COG categories were significantly enriched in DE genes from BAL-derived isolates, comprising four over-represented categories (*Carbohydrate transport and metabolism, Cell motility and secretion, Energy production and conversion* and *Intracellular trafficking and secretion*) that were majority downregulated and three under-represented categories (*Coenzyme metabolism, Function unknown,* and *Translation, ribosomal structure and biogenesis*). *** $p < 0.001$, ** $p < 0.01$, * $p < 0.05$.

Tables

Table 1. Summary of genomic and transcriptomic differences between paired, isogenic NTHi

isolates obtained from the nasopharynx (NP) and lower airways (bronchoalveolar lavage; BAL)

of 11 Australian children with chronic lung disease.

Patient ID	Site of isolation	Isolate no.	No. SNPs	No. indels	No. differentially expressed genes (up/down)	Genes with transcriptional and genetic alterations
60051	NP	1	0	1	58 (4/54)	*hsdM3*
	BAL	1				
60068	NP	3	0	1	54 (1/53)	---
	BAL	1				
60069	NP	2	0	1	0	---
	BAL	1				
60294	NP	1	0	0	0	---
	BAL	1				
60295	NP	1	1	0	46 (38/8)	---
	BAL	1				
60316	NP	1	0	0	0	---
	BAL	1				
60362	NP	1	0	0	15 (14/1)	---
	BAL	2				
60370	NP	2	0	0	2 (2/0)	---
	BAL	2				
60373_P1	NP	1	0	1*	5 (3/2)	*hsdM3*
	BAL	1				
60373_P2	NP	3	0	0	4 (4/0)	---
	BAL	4				
65001	NP	2	0	3	0	---
	BAL	1				
65290	NP	3	1	0	4 (4/0)	---
	BAL	4				

Abbreviations: SNP, single-nucleotide polymorphism; indel, insertion-deletion.

*The BAL strain from this patient contains a mixture of two deleterious indel mutations in *hsdM3* at a 40:60 ratio (See Figure 1).

Table 2. Summary of genetic variants identified between 12 paired, isogenic non-typeable *Haemophilus influenzae* isolates retrieved from the nasopharynx vs. lower airways (bronchoalveolar lavage; BAL).

Patient ID[a]	86-028NP Locus Tag	Gene	NP to BAL Genotype		Amino Acid Change (WT Length)	WT Isolate[b]	Mutation Effect in BAL isolate	Affected Protein	Protein Function	COG category[a]
60051	NTHI1838	hsdM3*	AAGACG	A	Glu9fs (556)	NP	Deleterious frameshift; premature stop yields 13aa product	Type I restriction enzyme HindVIIP M protein	DNA binding; site-specific DNA-methyltransferase (adenine-specific) activity	Defense mechanisms
60068	NTHI0782	hgpB*	GCCAACCAA	G	Thr35fs (992)	NP	Deleterious frameshift; premature stop yields 12aa product	Hemoglobin-haptoglobin binding protein B	Receptor and transporter activity	Inorganic ion transport and metabolism
60069	Intergenic	---	GATTATT	G	---	NP	Intergenic (62bp upstream of NTHI0369 [hxuC])	---	---	---
60295	NTHI0782	hgpB	C	T	Arg407Lys (992)	NP	Non-synonymous	Hemoglobin-haptoglobin binding protein B	Receptor and transporter activity	Inorganic ion transport and metabolism
60373_P1†	NTHI1838	hsdM3*	CGAGA (60%); CGAGACGAGA (40%)	A	Glu12fs (556)	NP	Deleterious frameshift; premature stop yields 16aa or 24aa product	Type I restriction enzyme HindVIIP M protein	DNA binding; site-specific DNA-methyltransferase (adenine-specific) activity	Defense mechanisms
65001	NTHI0472	lic3A*	TTTGA	T	Ser18fs (320)	NP	Deleterious frameshift; premature stop yields 36aa product	CMP-Neu5Ac--lipooligosaccharide alpha 2-3 sialyltransferase	Transferase activity; transfer of glycosyl groups	Cell envelope biogenesis
	NTHI0225	ompP2	C	CAGCAGTAGG	Ala269_Gly270insValGlyAla (365)	NP	In frame insertion of ValGlyAla; 368aa product	Outer membrane protein P2	Porin activity	Cell envelope biogenesis
	NTHI0315	hsdS2	ACTTACCAGCGAG	A	Thr173_Leu176del (390)	NP	In-frame deletion of 4aa	Type I restriction-modification system specificity protein	DNA binding and modification	Defense mechanisms
65290	NTHI1084	bamA	T	C	Glu508Gly (800)	NP	Non-synonymous	Protective surface antigen D15	Cell outer membrane assembly; protein insertion into membrane	Cell envelope biogenesis

[a]No genetic variants were found between the 60294, 60316, 60362, 60370 and 60373_P2 pairs; only pairs with genetic differences are shown

[b]Wild-type isolate is defined as the isolate which produces full length protein of similar aa length to 86-028NP reference

*Mutation found in a phase-variable region

†The BAL strain from this patient contains a mixture of two deleterious indel mutations in *hsdM3* at a 40:60 ratio (See Figure 1).

Abbrevations: aa, amino acid; BAL, bronchoalveolar lavage; COG, cluster of orthologous groups; NP; nasopharynx; WT, wild type

Supplemental material legends

Text S1. Supplementary methods.

Figure S1. Maximum parsimony phylogenomic analysis of non-typeable *Haemophilus*

influenzae isolates from paediatric lung disease against a global strain dataset.

Figure S2. Non-typeable *Haemophilus influenzae* growth kinetics in different growth media.

Table S1. Updated Cluster of Orthologous Group terms for non-typeable *Haemophilus*

influenzae strain 86-028NP. Figshare link: https://doi.org/10.6084/m9.figshare.7956191.v1

Table S2. Whole-genome sequencing and RNA sequencing summary information. Figshare

link: https://doi.org/10.6084/m9.figshare.7956194.v3

Dataset S1. Within-patient Non-typeable *Haemophilus influenzae* differential expression

analysis comparing nasopharynx against bronchoalveolar isolates. Figshare link:

https://doi.org/10.6084/m9.figshare.7956158.v1

Dataset S2. RNA sequencing raw read counts against Non-typeable *Haemophilus influenzae*

strain 86-028NP. Figshare link: https://doi.org/10.6084/m9.figshare.7956161.v1

References

1. Slack MPE. 2015. A review of the role of Haemophilus influenzae in community-acquired pneumonia. Pneumonia 6:26-43. doi: 10.15172/pneu.2015.6/520

2. Fothergill JL, Neill DR, Loman N, Winstanley C, Kadioglu A. 2014. *Pseudomonas aeruginosa* adaptation in the nasopharyngeal reservoir leads to migration and persistence in the lungs. Nat Commun 5:4780. doi: 10.1038/ncomms5780

3. Duell BL, Su YC, Riesbeck K. 2016. Host-pathogen interactions of nontypeable *Haemophilus influenzae*: from commensal to pathogen. FEBS Lett 590:3840-3853. doi: 10.1002/1873-3468.12351

4. Van Eldere J, Slack MPE, Ladhani S, Cripps AW. 2014. Non-typeable *Haemophilus influenzae*, an under-recognised pathogen. Lancet Infect Dis 14:1281-1292. doi: 10.1016/s1473-3099(14)70734-0

5. Wurzel DF, Marchant JM, Yerkovich ST, Upham JW, Petsky HL, Smith-Vaughan H, Masters B, Buntain H, Chang AB. 2016. Protracted Bacterial Bronchitis in Children: Natural History and Risk Factors for Bronchiectasis. Chest 150:1101-1108. doi: 10.1016/j.chest.2016.06.030

6. Byun MK, Chang J, Kim HJ, Jeong SH. 2017. Differences of lung microbiome in patients with clinically stable and exacerbated bronchiectasis. PLoS One 12:e0183553. doi: 10.1371/journal.pone.0183553

7. Martinez-Garcia MA, Soler-Cataluna JJ, Donat Sanz Y, Catalan Serra P, Agramunt Lerma M, Ballestin Vicente J, Perpina-Tordera M. 2011. Factors associated with bronchiectasis in patients with COPD. Chest 140:1130-1137. doi: 10.1378/chest.10-1758

8. Sriram KB, Cox AJ, Clancy RL, Slack MPE, Cripps AW. 2018. Nontypeable *Haemophilus influenzae* and chronic obstructive pulmonary disease: a review for clinicians. Crit Rev Microbiol 44:125-142. doi: 10.1080/1040841X.2017.1329274

9. Tufvesson E, Bjermer L, Ekberg M. 2015. Patients with chronic obstructive pulmonary disease and chronically colonized with *Haemophilus influenzae* during stable disease phase have increased airway inflammation. Int J Chronic Obstr 10:881-889. doi: 10.2147/Copd.S78748

10. Murphy TF, Kirkham C. 2002. Biofilm formation by nontypeable *Haemophilus influenzae*: strain variability, outer membrane antigen expression and role of pili. BMC Microbiol 2:7. doi: 10.1186/1471-2180-2-7

11. Swords WE. 2012. Nontypeable *Haemophilus influenzae* biofilms: role in chronic airway infections. Front Cell Infect Microbiol 2:97. doi: 10.3389/fcimb.2012.00097

12. Starner TD, Zhang N, Kim G, Apicella MA, McCray PB, Jr. 2006. *Haemophilus influenzae* forms biofilms on airway epithelia: implications in cystic fibrosis. Am J Respir Crit Care Med 174:213-20. doi: 10.1164/rccm.200509-1459OC

13. Slack MPE. 2017. The evidence for non-typeable *Haemophilus influenzae* as a causative agent of childhood pneumonia. Pneumonia 9. doi: 10.1186/s41479-017-0033-2

14. Power PM, Bentley SD, Parkhill J, Moxon ER, Hood DW. 2012. Investigations into genome diversity of *Haemophilus influenzae* using whole genome sequencing of clinical isolates and laboratory transformants. Bmc Microbiol 12:273. doi: 10.1186/1471-2180-12-273

15. Erwin AL, Nelson KL, Mhlanga-Mutangadura T, Bonthuis PJ, Geelhood JL, Morlin G, Unrath WC, Campos J, Crook DW, Farley MM, Henderson FW, Jacobs RF, Muhlemann K, Satola SW, van Alphen L, Golomb M, Smith AL. 2005. Characterization of genetic and phenotypic diversity of invasive nontypeable *Haemophilus influenzae*. Infect Immun 73:5853-63. doi: 10.1128/IAI.73.9.5853-5863.2005

16. Wong SM, Akerley BJ. 2012. Genome-scale approaches to identify genes essential for *Haemophilus influenzae* pathogenesis. Front Cell Infect Microbiol 2:23. doi: 10.3389/fcimb.2012.00023

17. Pettigrew MM, Ahearn CP, Gent JF, Kong Y, Gallo MC, Munro JB, D'Mello A, Sethi S, Tettelin H, Murphy TF. 2018. *Haemophilus influenzae* genome evolution during persistence in the human airways in chronic obstructive pulmonary disease. Proc Natl Acad Sci U S A doi:10.1073/pnas.1719654115. doi: 10.1073/pnas.1719654115

18. Baddal B, Muzzi A, Censini S, Calogero RA, Torricelli G, Guidotti S, Taddei AR, Covacci A, Pizza M, Rappuoli R, Soriani M, Pezzicoli A. 2015. Dual RNA-seq of Nontypeable *Haemophilus influenzae* and Host Cell Transcriptomes Reveals Novel Insights into Host-Pathogen Cross Talk. MBio 6:e01765-15. doi: 10.1128/mBio.01765-15

19. Connor TR, Corander J, Hanage WP. 2012. Population subdivision and the detection of recombination in non-typable *Haemophilus influenzae*. Microbiology 158:2958-64. doi: 10.1099/mic.0.063073-0

20. Price EP, Sarovich DS, Mayo M, Tuanyok A, Drees KP, Kaestli M, Beckstrom-Sternberg SM, Babic-Sternberg JS, Kidd TJ, Bell SC, Keim P, Pearson T, Currie BJ. 2013. Within-host evolution of *Burkholderia pseudomallei* over a twelve-year chronic carriage infection. MBio 4(4):e00388-13. doi: 10.1128/mBio.00388-13

21. Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, D'Argenio DA, Miller SI, Ramsey BW, Speert DP, Moskowitz SM, Burns JL, Kaul R, Olson MV. 2006. Genetic adaptation by *Pseudomonas aeruginosa* to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A 103:8487-92. doi: 10.1073/pnas.0602138103

22. De Chiara M, Hood D, Muzzi A, Pickard DJ, Perkins T, Pizza M, Dougan G, Rappuoli R, Moxon ER, Soriani M, Donati C. 2014. Genome sequencing of disease and carriage isolates of nontypeable *Haemophilus influenzae* identifies discrete population structure. Proc Natl Acad Sci U S A 111:5439-44. doi: 10.1073/pnas.1403353111

23. Hare KM, Grimwood K, Leach AJ, Smith-Vaughan H, Torzillo PJ, Morris PS, Chang AB. 2010. Respiratory bacterial pathogens in the nasopharynx and lower airways of Australian indigenous children with bronchiectasis. J Pediatr 157:1001-5. doi: 10.1016/j.jpeds.2010.06.002

24. Gibson LF, Khoury JT. 1986. Storage and Survival of Bacteria by Ultra-Freeze. Lett Appl Microbiol 3:127-129. doi: 10.1111/j.1472-765X.1986.tb01565.x

25. Price EP, Harris TM, Spargo J, Nosworthy E, Beissbarth J, Chang AB, Smith-Vaughan HC, Sarovich DS. 2017. Simultaneous identification of *Haemophilus influenzae* and *Haemophilus haemolyticus* using real-time PCR. Future Microbiol 12:585-593. doi: 10.2217/fmb-2016-0215

26. Bell SM, Pham JN, Rafferty DL, Allerton JK. 2016. Antibiotic Susceptibility Testing By the CDS Method (8th Edition). http://cdstest.net/wordpress/wp-content/uploads/Antibiotic-Susceptibility-Testing-by-the-CDS-Method-8th-Edition.pdf. Accessed 25/03/2019.

27. Price EP, Sarovich DS, Nosworthy E, Beissbarth J, Marsh RL, Pickering J, Kirkham LA, Keil AD, Chang AB, Smith-Vaughan HC. 2015. *Haemophilus influenzae*: using comparative genomics to accurately identify a highly recombinogenic human pathogen. BMC Genomics 16:641. doi: 10.1186/s12864-015-1857-x

28. Jolley KA, Maiden MC. 2010. BIGSdb: Scalable analysis of bacterial genome variation at the population level. BMC Bioinformatics 11:595. doi: 10.1186/1471-2105-11-595

29. Sarovich DS, Price EP. 2014. SPANDx: a genomics pipeline for comparative analysis of large haploid whole genome re-sequencing datasets. BMC Res Notes 7:618. doi: 10.1186/1756-0500-7-618

30. Holt LB. 1962. The growth-factor requirements of *Haemopiius influenzae*. J Gen Microbiol 27:317-22. doi: 10.1099/00221287-27-2-317

31. Fung C, Naughton S, Turnbull L, Tingpej P, Rose B, Arthur J, Hu H, Harmer C, Harbour C, Hassett DJ, Whitchurch CB, Manos J. 2010. Gene expression of *Pseudomonas aeruginosa* in a mucin-containing synthetic growth medium mimicking cystic fibrosis lung sputum. J Med Microbiol 59:1089-100. doi: 10.1099/jmm.0.019984-0

32. Artman M, Domenech E, Weiner M. 1983. Growth of *Haemophilus influenzae* in simulated blood cultures supplemented with hemin and NAD. J Clin Microbiol 18:376-9. doi:

33. Aziz A, Sarovich DS, Harris TM, Kaestli M, McRobb E, Mayo M, Currie BJ, Price EP. 2017. Suspected cases of intracontinental *Burkholderia pseudomallei* sequence type homoplasy resolved using whole-genome sequencing. Microb Genom 3. doi: 10.1099/mgen.0.000139

34. Humair PF, Douet V, Moran Cadenas F, Schouls LM, Van De Pol I, Gern L. 2007. Molecular identification of bloodmeal source in *Ixodes ricinus* ticks using 12S rDNA as a genetic marker. J Med Entomol 44:869-80. doi: 10.1093/jmedent/44.5.869

35. Robinson MD, McCarthy DJ, Smyth GK. 2010. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26:139-40. doi: 10.1093/bioinformatics/btp616

36. R Core Team. 2014. R: A language and environment for statistical computing, R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/.

37. Galperin MY, Makarova KS, Wolf YI, Koonin EV. 2015. Expanded microbial genome coverage and improved protein family annotation in the COG database. Nucleic Acids Res 43:D261-9. doi: 10.1093/nar/gku1223

38. Santana EA, Harrison A, Zhang XJ, Baker BD, Kelly BJ, White P, Liu YL, Munson RS. 2014. HrrF Is the Fur-Regulated Small RNA in Nontypeable *Haemophilus influenzae*. Plos One 9. doi: 10.1371/journal.pone.0105644

39. Zaleski P, Wojciechowski M, Piekarowicz A. 2005. The role of Dam methylation in phase variation of *Haemophilus influenzae* genes involved in defence against phage infection. Microbiology 151:3361-9. doi: 10.1099/mic.0.28184-0

40. Coleman HN, Daines DA, Jarisch J, Smith AL. 2003. Chemically defined media for growth of *Haemophilus influenzae* strains. J Clin Microbiol 41:4408-10. doi: 10.1128/JCM.41.9.4408-4410.2003

41. Kasi AS, Neubauer C, Kato RM, Newman DK. 2017. Bacterial Growth Rate In Cystic Fibrosis Pulmonary Exacerbation. Am J Respir Crit Care Med 195. doi: 10.1164/ajrccm-conference.2017.195.1_MeetingAbstracts.A4856

42. Yang L, Haagensen JA, Jelsbak L, Johansen HK, Sternberg C, Hoiby N, Molin S. 2008. *In situ* growth rates and biofilm development of *Pseudomonas aeruginosa* populations in chronic lung infections. J Bacteriol 190:2767-76. doi: 10.1128/JB.01581-07

43. Erwin AL, Smith AL. 2007. Nontypeable *Haemophilus influenzae*: understanding virulence and commensal behavior. Trends Microbiol 15:355-62. doi: 10.1016/j.tim.2007.06.004

44. Murphy TF. 2003. Respiratory infections caused by non-typeable *Haemophilus influenzae*. Curr Opin Infect Dis 16:129-34. doi: 10.1097/01.aco.0000065079.06965.e0

45. Purcell P, Jary H, Perry A, Perry JD, Stewart CJ, Nelson A, Lanyon C, Smith DL, Cummings SP, De Soyza A. 2014. Polymicrobial airway bacterial communities in adult bronchiectasis patients. BMC Microbiol 14:130. doi: 10.1186/1471-2180-14-130

46. Moleres J, Fernandez-Calvet A, Ehrlich RL, Marti S, Perez-Regidor L, Euba B, Rodriguez-Arce I, Balashov S, Cuevas E, Linares J, Ardanuy C, Martin-Santamaria S, Ehrlich GD, Mell JC, Garmendia J. 2018. Antagonistic Pleiotropy in the Bifunctional Surface Protein FadL (*OmpP1*) during Adaptation of *Haemophilus influenzae* to Chronic Lung Infection Associated with Chronic Obstructive Pulmonary Disease. MBio 9. doi: 10.1128/mBio.01176-18

47. Grønseth R, Drengenes C, Wiker HG, Tangedal S, Xue Y, Husebø GR, Svanes Ø, Lehmann S, Aardal M, Hoang T, Kalananthan T, Hjellestad Martinsen EM, Orvedal Leiten E, Aanerud M, Nordeide E, Haaland I, Jonassen I, Bakke P, Eagan T. 2017. Protected sampling is preferable in bronchoscopic studies of the airway microbiome. ERJ Open Research 3:00019-2017. doi: 10.1183/23120541.00019-2017

48. Gilsdorf JR, Marrs CF, Foxman B. 2004. *Haemophilus influenzae:* Genetic Variability and Natural Selection To Identify Virulence Factors. Infect Immun 72:2457-2461. doi: 10.1128/iai.72.5.2457-2461.2004

49. Vasu K, Nagaraja V. 2013. Diverse functions of restriction-modification systems in addition to cellular defense. Microbiol Mol Biol Rev 77:53-72. doi: 10.1128/MMBR.00044-12

50. De Ste Croix M, Vacca I, Kwun MJ, Ralph JD, Bentley SD, Haigh R, Croucher NJ, Oggioni MR. 2017. Phase-variable methylation and epigenetic regulation by type I restriction-modification systems. FEMS Microbiol Rev 41:S3-S15. doi: 10.1093/femsre/fux025

51. Poole J, Foster E, Chaloner K, Hunt J, Jennings MP, Bair T, Knudtson K, Christensen E, Munson RS, Jr., Winokur PL, Apicella MA. 2013. Analysis of nontypeable *Haemophilus influenzae* phase-variable genes during experimental human nasopharyngeal colonization. J Infect Dis 208:720-7. doi: 10.1093/infdis/jit240

52. Hosking SL, Craig JE, High NJ. 1999. Phase variation of *lic1A*, *lic2A* and *lic3A* in colonization of the nasopharynx, bloodstream and cerebrospinal fluid by *Haemophilus influenzae* type b. Microbiology 145(11):3005-11. doi: 10.1099/00221287-145-11-3005

53. Hood DW, Cox AD, Gilbert M, Makepeace K, Walsh S, Deadman ME, Cody A, Martin A, Mansson M, Schweda EK, Brisson JR, Richards JC, Moxon ER, Wakarchuk WW. 2001. Identification of a lipopolysaccharide alpha-2,3-sialyltransferase from *Haemophilus influenzae*. Mol Microbiol 39:341-50. doi: doi.org/10.1046/j.1365-2958.2001.02204.x

54. Murray NE. 2000. Type I restriction systems: sophisticated molecular machines (a legacy of Bertani and Weigle). Microbiol Mol Biol Rev 64:412-34. doi: 10.1128/MMBR.64.2.412-434.2000

55. Atack JM, Srikhanta YN, Fox KL, Jurcisek JA, Brockman KL, Clark TA, Boitano M, Power PM, Jen FEC, McEwan AG, Grimmond SM, Smith AL, Barenkamp SJ, Korlach J, Bakaletz LO, Jennings MP. 2015. A biphasic epigenetic switch controls immunoevasion, virulence and niche adaptation in non-typeable *Haemophilus influenzae*. Nat Commun 6. doi: 10.1038/ncomms8828

56. Sikkema DJ, Murphy TF. 1992. Molecular analysis of the P2 porin protein of nontypeable *Haemophilus influenzae*. Infect Immun 60:5204-11. doi:

57. Fox KL, Dowideit SJ, Erwin AL, Srikhanta YN, Smith AL, Jennings MP. 2007. *Haemophilus influenzae* phasevarions have evolved from type III DNA restriction systems into epigenetic regulators of gene expression. Nucleic Acids Research 35:5242-5252. doi: 10.1093/nar/gkm571

58. Bakaletz LO, Baker BD, Jurcisek JA, Harrison A, Novotny LA, Bookwalter JE, Mungur R, Munson RS. 2005. Demonstration of type IV pilus expression and a twitching phenotype by *Haemophilus influenzae*. Infect Immun 73:1635-1643. doi: 10.1128/IAI.73.3.1635-1643.2005

59. Jurcisek JA, Bookwalter JE, Baker BD, Fernandez S, Novotny LA, Munson RS, Jr., Bakaletz LO. 2007. The PilA protein of non-typeable *Haemophilus influenzae* plays a role in biofilm formation, adherence to epithelial cells and colonization of the mammalian upper respiratory tract. Mol Microbiol 65:1288-99. doi: 10.1111/j.1365-2958.2007.05864.x

60. Apicella MA. 2012. Nontypeable *Haemophilus influenzae*: the role of N-acetyl-5-neuraminic acid in biology. Front Cell Infect Microbiol 2:19. doi: 10.3389/fcimb.2012.00019

61. Mandrell RE, McLaughlin R, Aba Kwaik Y, Lesse A, Yamasaki R, Gibson B, Spinola SM, Apicella MA. 1992. Lipooligosaccharides (LOS) of some *Haemophilus* species mimic human glycosphingolipids, and some LOS are sialylated. Infect Immun 60:1322-8. doi:

62. Lim YW, Schmieder R, Haynes M, Willner D, Furlan M, Youle M, Abbott K, Edwards R, Evangelista J, Conrad D, Rohwer F. 2013. Metagenomics and metatranscriptomics: windows on CF-associated viral and microbial communities. J Cyst Fibros 12:154-64. doi: 10.1016/j.jcf.2012.07.009

63. Viberg LT, Sarovich DS, Kidd TJ, Geake JB, Bell SC, Currie BJ, Price EP. 2017. Within-Host Evolution of *Burkholderia pseudomallei* during Chronic Infection of seven Australasian cystic fibrosis patients. MBio 8:e00356-17. doi: 10.1128/mBio.00356-17